Assenagon Asset Management S.A. grew its stake in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD – Get Rating) by 8.5% in the third quarter, according to the company in its most recent filing with the SEC. The firm owned 147,636 shares of the biotechnology company's stock after acquiring an additional 11,527 shares during the quarter. Assenagon Asset Management S.A. owned about 0.10% of Ironwood Pharmaceuticals worth $1,530,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of IRWD. Gladius Capital Management LP bought a new stake in shares of Ironwood Pharmaceuticals during the 2nd quarter valued at $55,000. Banque Cantonale Vaudoise bought a new stake in shares of Ironwood Pharmaceuticals during the 2nd quarter valued at $58,000. Captrust Financial Advisors lifted its position in shares of Ironwood Pharmaceuticals by 441.7% during the 2nd quarter. Captrust Financial Advisors now owns 6,690 shares of the biotechnology company's stock valued at $77,000 after acquiring an additional 5,455 shares during the period. Lazard Asset Management LLC bought a new stake in shares of Ironwood Pharmaceuticals during the 1st quarter valued at $78,000. Finally, Quantbot Technologies LP bought a new stake in shares of Ironwood Pharmaceuticals during the 1st quarter worth $109,000.

Insiders Place Their Bets

In other Ironwood Pharmaceuticals news, CEO Thomas A. Mccourt sold 110,962 shares of the company's stock in a transaction dated Thursday, January 5th. The stock was sold at an average price of $12.07, for a total value of $1,339,311.34. Following the completion of the transaction, the chief executive officer now owns 712,440 shares of the company's stock, valued at approximately $8,599,150.80. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 13.10% of the company's stock.

Ironwood Pharmaceuticals Price Performance

Ironwood Pharmaceuticals (NASDAQ:IRWD – Get Rating) last announced its quarterly earnings data on Thursday, November 3rd. The biotechnology company reported $0.28 earnings per share for the quarter, topping the consensus estimate of $0.27 by $0.01. Ironwood Pharmaceuticals had a return on equity of 30.24% and a net margin of 39.85%. The business had revenue of $108.64 million during the quarter, compared to the consensus estimate of $111.51 million. On average, sell-side analysts forecast that Ironwood Pharmaceuticals, Inc. will post 1.01 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, StockNews.com downgraded Ironwood Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Saturday, December 17th. One analyst has rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $14.67.

About Ironwood Pharmaceuticals

(Get Rating)

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union.

Read More

• Get a free copy of the StockNews.com research report on Ironwood Pharmaceuticals (IRWD)
• MarketBeat: Week in Review 01/09-01/13
• JPMorgan Chase Falls As Banks Brace For Recession
• Why is the Bed Bath & Beyond Stock Price up 261%?
• Roku Stock Price is Trending, Here's Why
• Carvana Stock Rally, Here's What You Need to Know

Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.